logo
Share SHARE
FONT-SIZE Plus   Neg

Novartis: Omalizumab Met All Goals In Phase III Safety Registration Study In CSU

Swiss drugmaker Novartis AG (NVS) Wednesday announced late-breaking results showing
omalizumab met all primary and secondary endpoints of a pivotal Phase III safety registration study in chronic spontaneous urticaria or CSU, a chronic and debilitating form of hives with limited approved treatment options.

GLACIAL is the second of three pivotal Phase III studies that examine the efficacy and safety of omalizumab in CSU.

The study results supported the efficacy, safety and tolerability of omalizumab in patients with refractory CSU, a chronic and debilitating skin disease with intractable itch and hives.

Up to 40 percent of CSU patients fail on antihistamines, even those taking up to four times the approved dose. Antihistamines, at the approved dose, are currently the only licensed treatment for CSU.

Omalizumab is not currently approved or indicated for CSU. Regulatory submissions for omalizumab in CSU are on track for later this year, Novartis noted. It is being jointly developed by Novartis and Genentech, Inc.

The data was presented for the first time at the European Academy of Allergy and Clinical Immunology-World Allergy Organization World Allergy and Asthma Congress 2013 in Milan, Italy.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Royal Bank of Canada got the highest ranking in overall customer satisfaction among the five biggest Canadian banks, according to the results of an annual survey released Thursday. The lender toppled Toronto-Dominion Bank, which had held the top spot for the past ten years. Ford Motor Co.(F) reported a profit for the second-quarter that declined 8.8 percent from last year, while total revenue increased about 6 percent. The company now sees risks challenging achieving 2016 guidance. ConocoPhillips on Thursday reported a loss for the second quarter that widened from last year, reflecting lower revenues and one-time charges. The results for the quarter missed analysts' estimates. However, the company raised its production outlook for the full-year. Like other companies in the oil industry, ConocoPhillips is struggling with lower oil prices.
comments powered by Disqus
Follow RTT